Halogenated pyrimidines are incorporated in place of thymidine in DNA of replicating cells, making the cells more susceptible to the effects of radiation. 5-Bromo-2Ј-deoxyuridine (BrdUrd) has been clinically used as a radiosensitizer to enhance the tumor killing effect of radiation therapy.
4-OH-CPA exists in equilibrium with aldophosphamide, which is broken down to form the DNA cross-linking agent phosphoramide mustard and the toxic metabolite acrolein. [11] [12] [13] The alternative pathway involves a CYP3A4-mediated N-dechloroethylation of CPA to form the inactive metabolite 3-dechloroethylcyclophosphamide (DECP) and the toxic byproduct chloroacetaldehyde. 11, 14, 15) In humans, this pathway is secondary to the activation pathway and accounts for less than 10% of the dose. 13) Alkylating agents undergo a transformation to produce highly reactive and positively charged ions. These ions can then form covalent bonds with electron-rich sites on biological molecules, such as nucleic acids, proteins, and amino acids. 16) Irradiation may cause the ablation of both singleand double-stranded DNA, degeneration or loss of bases, and intercalation of DNA and/or chromosomal protein. The actions of alkylating agents appear to have some similarities to those of gamma ray radiation. A previous in vitro report showed that pretreatment with iododeoxyuridine (IdUrd) or BrdUrd enhanced the cytotoxicity of various antineoplasmic agents, such as melphalan, cisplatin, doxorubicin, and bleomycin. 17) However, the mechanism of halopyrimidine's chemosensitizing effect is still unclear. There have been few in vivo studies on the combined antitumor effects of halogenated pyrimidines and alkylating agents. We investigated here the combined effect of BrdUrd and CPA, a bifunctional alkylating agent, on life span in L1210 ascites tumor-bearing mice and cytotoxicity in cultured L1210 cells using an MTT assay.
MATERIALS AND METHODS

Chemicals
BrdUrd was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). CPA and 4-hydroxy-cyclophosphamide (4-OH-CPA), an active form in men, were obtained from Shionogi Pharmaceutical Co., Ltd. (Osaka, Japan). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Chemical Co.
Life Prolongation Study Male BDF1 mice were purchased from Shionogi Pharmaceutical Co., Ltd. and kept at Mie University Animal Center under constant conditions (a 12 h light : 12 h dark regimen with Oriental Chow pellet food and water freely available). L1210 leukemia cells were obtained from Shionogi Pharmacological Laboratory, Osaka, Japan and maintained in BDF1 mice by weekly intraperitoneal (i.p.) passage as previously described. 18) Experimental mice received an i.p. injection of 1ϫ10 6 ascites tumor cells in saline on Day 0. Seventy mice were randomly divided into 7 groups. CPA and BrdUrd were prepared just before use by dissolving in saline. Either 100 or 200 mg/kg of BrdUrd was given i.p. to mice 24 h after the tumor inoculation and this was repeated once daily for five consecutive days (Day 1 to 5). A single dose of CPA (80 or 160 mg/kg) was given i.p. to mice on Day 5. To evaluate the combined effect of BrdUrd and CPA, 100 mg/kg of BrdUrd was administered i.p. for five consecutive days (Day 1 to Day 5) and a single dose (80 mg/kg) of CPA was administered i.p. just after the BrdUrd dose on Day 5. To investigate the antitumor effect of CPA in the early period, when tumor cells have yet to enter a proliferative phase, one group of mice was given a single i.p. dose (80 mg/kg) of CPA at Day 1. Saline was given to the control groups using the same schedule.
In Vitro Assay L1210 leukemia cells were obtained from Shionogi Pharmacological Laboratory. Cells were fed twice weekly with RPMI 1640 medium supplemented with 10% bovine serum (ICN Biomedicals, Aurora, Ohio, U.S.A.), 0.2% sodium bicarbonate, and 5 mM mercaptoethanol solution, and grown at 37°C in a humidified incubator with 5% CO 2 .
Cells in an exponential phase of growth were used in experiments. An MTT assay was performed to measure cell survival. [19] [20] [21] Cells were seeded in 96-well plates at 1ϫ10 5 cells/well and incubated for 48 h with or without 0.1 to 0.4 mg/ml of BrdUrd before the addition of 4-OH-CPA. Twenty four hours after the pretreatment with BrdUrd, various concentrations of 4-OH-CPA were added into the wells. Twenty four hours after the treatment with 4-OH-CPA, 10 ml of MTT was added to each well, and the plate was incubated for 4 h at 37°C. The MTT crystals were solubilized by the addition of 100 ml of acid isopropyl alcohol. The spectrophotometric absorbance of each sample was measured at 570 nm using a Dynatech MR5000 Microplate Reader (Chantilly, VA, U.S.A.). Each datum was expressed as an average of measurements obtained from 6 wells.
To determine whether the two drugs exhibited synergistic cytotoxic effects, the data from the dose-response curves was examined by constructing isobolograms. 22, 23) Statistical Analysis The statistical analysis was performed using the StatView version 5 program (Hulinks, Tokyo, Japan). Scheffe's F test was performed to compare the survival times of the mice, and pϽ0.05 was considered significant.
RESULTS
BDF1 mice bearing L1210 ascites tumors intraperitoneally received two types of a single dose of CPA 5 d after the tumor inoculation with or without a concomitant administration of BrdUrd. Figure 1 shows the life span of the tumorbearing mice. One hundred and sixty mg/kg of CPA alone significantly extended the life of these mice compared with the control group that received saline (pϽ0.001), but 80 mg/kg of CPA did not (pϭ0. Mice in the control, BrdUrd 100 mg/kg, and BrdUrd 200 mg/kg groups gradually increased in weight 5 to 7 d after the tumor inoculation, with an increase of more than 10% compared to levels before the tumor inoculation (Fig. 2) . Most of the mice died a few days after the increase in weight An MTT assay was performed using the leukemic cell line L1210. Figure 3 shows that 24 h of treatment with 4-OH-CPA killed L1210 cells in a dose-dependent manner, and the IC 50 value was 1.27 mg/ml. Three concentrations of BrdUrd were added to the culture medium 24 h before the addition of 4-OH-CPA. In contrast to the result in tumor-bearing mice, the 48-h treatment with BrdUrd alone had an apparent cytotoxic effect in vitro and the IC 50 value was 0.41 mg/ml (Fig.  4) . BrdUrd at 0.1, 0.2, or 0.4 mg/ml enhanced the cytotoxicity of 4-OH-CPA in a concentration-dependent manner. The isobologram at the IC 50 of 4-OH-CPA showed that 0.1 mg/ml of BrdUrd synergistically affected the cytotoxicity of 4-OH-CPA, but 0.2 mg/ml of BrdUrd seemed to have an additive effect (Fig. 5) . The isobologram at the IC 75 of 4-OH-CPA showed that at 0.1, 0.2, and 0.4 mg/ml, BrdUrd had a synergistic effect on the cytotoxicity of 4-OH-CPA. We also examined cytotoxicity produced by the simultaneous treatment of 4-OH-CPA and BrdUrd for 48 h against the L1210 cells. No enhanced cytotoxicity was produced by the simultaneous treatment of those two drugs (data not shown).
DISCUSSION
Our results showed that oral coadministration of BrdUrd (100 mg/kg) with CPA (80 mg/kg) significantly extended the life span of mice bearing L1210 ascites tumors, compared with the mice given CPA (80 mg/kg) alone or the control group. Although the antitumor effect of 160 mg/kg of CPA alone was comparable to that of CPA (80 mg/kg) coadministered with BrdUrd (100 mg/kg), some of the mice that received 160 mg/kg of CPA died a few days later. Since the LD 50 value, which shows the acute toxicity of CPA in mice, was estimated to be about 300 mg/kg, the early death possibly reflects the toxicity of the high dose of CPA. 24) In contrast, concomitant use of 80 mg/kg of CPA and 100 mg/kg of BrdUrd did not cause early death. This result indicates that the concomitant use of CPA and BrdUrd did not elevate serum concentrations of CPA or its active metabolites. Neither 100 mg/kg or two doses of BrdUrd alone extended the life span of mice. These results suggested that BrdUrd increased the antitumor effect of CPA in vivo without early death, and acted as a biochemical modulator of CPA. Halogenated pyrimidines are incorporated in place of thymidine in DNA of replicating cells. The accumulated amount of analogues in DNA correlates with the magnitude of radiosensitization in tumor cells. 25) Repeated administration of BrdUrd might cause accumulation of the halogenated analogue in DNA, and tumor cells might be more susceptible to CPA. It was, however, not clear whether the accumulation of BrdUrd into DNA was essential or not for the combined effect because we did not examine the combined effect of a single dose of BrdUrd and CPA. CPA (80 mg/kg) administered 1 d after the tumor inoculation significantly increased life span, while the same dose of CPA administered 5 d after the tumor inoculation did not. It is generally thought that the administration of anticancer drugs is more advantages to the host before than after the drastic proliferation of tumor cells. Concomitant administration of CPA (80 mg/kg) with BrdUrd (100 mg/kg) extended life more than CPA alone administered 1 d after the tumor inoculation. This result indicated that the combination of CPA and BrdUrd could overcome the disadvantage of being treated after an increase in the number of tumor cells. BrdUrd had been clinically used as a radiosensitizer to enhance the antitumor effect of radiation therapy in Japan. CPA is one of the most popular anticancer agents for the treatment of hematological cancers. Concomitant use of BrdUrd and CPA might be a promising combination for the treatment of human cancers.
The weight of mice after the tumor inoculation showed interesting changes. The mean weight of mice peaked a few days before their death. The weight of mice who received CPA with BrdUrd, or 160 mg/kg of CPA alone, increased 5 to 6 d after the tumor inoculation, and then decreased to the level before the inoculation. It then increased a few days after their death. These results suggested that the increase in body weight that indicated the proliferation of tumor cells might not directly cause death.
To elucidate the enhanced antitumor effect of CPA in combination with BrdUrd, we investigated the influence of BrdUrd on the cytotoxicity of CPA using the L1210 cultured cell line in vitro. Since CPA is a prodrug and is metabolized to an active form, 4-OH-CPA, in the liver after administration, we used 4-OH-CPA in an in vitro assay. While BrdUrd did not show antitumor activity in vivo, 24 h of treatment with BrdUrd in vitro had a concentration-dependent cytotoxic effect in the L1210 cells above a concentration of 0.1 mg/ml. 4-OH-CPA was more cytotoxic in combination with BrdUrd, as shown in the in vivo experiment. Isobolograms of IC 50 and IC 75 showed that pretreatment with BrdUrd enhanced the cytotoxicity of 4-OH-CPA, consistent with the result of the in vivo assay. In case of IC 50 of 4-OH-CPA, however, we can not conclude whether the combined effect of CPA and BrdUrd was synergistic or additive because of a small number of the data points. These results suggest that the enhanced cell killing contributed to the extended life span of tumor-bearing mice when CPA was used in combination with BrdUrd. To confirm the direct relationship between the tumor cell killing and the extended life span, counting the tumor cell numbers and measuring the ascites volume are needed using tumor-bearing mice.
BrdUrd had a dose-dependent cytotoxic effect on L1210 cells in the MTT assay. Its cytotoxic efficacy (IC 50 : 0.41 mg/ml) was greater than that of 4-OH-CPA (IC 50 : 1.27 mg/ml), while the treatment time (48 h) was twice as long as that with 4-OH-CPA (24 h). We did not measure the drug concentration of BrdUrd in mice or the culture medium. The hepatic extraction rate for BrdUrd was reported to be high in dogs. 26) BrdUrd administered intraperitoneally to mice was eliminated quickly and only a small amount of the drug reached the tumor cells, while BrdUrd added into the culture medium might remain at a high concentration for several hours. The 5-halogenated analogues of deoxyuridine was reported to induce cytotoxicity against tumor cells in the absence of radiation, and the clinical utilization of those analogues might be limited to specific cancers. 27) The difference in the time-concentration relationship or time of drug exposure might cause the different results in vivo versus in vitro. We also could not exclude the possibility that degradation products of BrdUrd in the culture medium influenced the survival of tumor cells. Moreover, CPA is converted not only to 4-OH-CPA, but also to another active metabolite, aldophosphamide. [11] [12] [13] 28) Aldophosphamide generates highly active and toxic compounds, phosphoramide mustard and acrolein. We used only 4-OH-CPA as an active form of CPA in vitro. Aldophosphamide, phosphoramide mustard, and acrolein are highly unstable and we could not examine their cytotoxic effect in an MTT assay. These other metabolites might contribute to the stronger antitumor effect of CPA in vivo.
In the MTT assay, IC 50 values of 4-OH-CPA after the pretreatment of BrdUrd seemed to be a less than synergistic effect, while the IC 75 values showed a synergistic one. Although we did not know the exact reason of the difference, the fact that a significant amount of the tumor cells were killed after the pretreatment of more than 0.1 mg/ml of BrdUrd, might influence the cytotoxicity of 4-OH-CPA. Because for cancer chemotherapeutic agents the drug concentrations that are of most interest are those that produce cell killing, the result of IC 75 values is thought to be more important than those of IC 50 . 29) In conclusion, BrdUrd effectively enhanced the antitumor effect of CPA in mice bearing L1210 ascites tumors. MTT assays in vitro partly reproduced the combined effect. These results indicated that concomitant use of CPA and BrdUrd may be promising for cancer chemotherapy. Further study is needed to confirm the combined effect of CPA and BrdUrd using other mice species and other tumor cell lines, and to elucidate how this combination acts.
